Genfleet Therapeutics (Shanghai) Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jun 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 4, 2027The maintenance fee for Benzotriazole-Derived Alpha and Beta-Unsaturated Amide Compound Used as Tgf-Beta Ri Inhibitor (US 10,548,883) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,548,883 | Benzotriazole-Derived Alpha and Beta-Unsaturated Amide Compound Used as Tgf-Beta Ri Inhibitor In force · High confidence | In force | High confidence | |
| US 10,952,999 | Inhibitor of cyclin-dependent kinase CDK9 In force · USPTO record | In force | USPTO record | |
| US 11,236,112 | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor In force · USPTO record | In force | USPTO record | |
| US 12,054,497 | Substituted Heterocyclic Fused Cyclic Compound, Preparation Method Therefor and Pharmaceutical Use Thereof In force · High confidence | In force | High confidence | |
| US 12,384,774 | Polymorph of CDK9 inhibitor and preparation method for polymorph and use thereof In force · USPTO record | In force | USPTO record | |
| US 12,692,275 | Aroyl Substituted Tricyclic Compound, Preparation Method Therefor and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,667,559 | Dihydronaphthyridinone Compound, and Preparation Method Therefor and Medical Use Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 abandoned · 7 no status recorded